All Posts

HM.BioConsulting Spotlight Series ISSUE 10-1 · MAY 2026 A Strategic Intelligence Report by Henning Mann, HM.BioConsulting, Emma Aitken, Australian Trade & Investment Commission, Michael Phelan, InnovApproach Consulting Prepared by Henning Mann, PhD | Founder & Principal, HM.BioConsulting May 2026 Get the Full Article PDF EXECUTIVE SUMMARY Australia has quietly become a powerful launchpad for early-phase clinical development, and a rising hub for New Approach Meth

A Conversation between Rebecca Clyde, PhD, Botco.ai, and Henning Mann, PhD, HM.BioConsulting Authors: Rebecca Clyde, Desiree Goubert, Henning Mann Clinical trial matching is entering a new phase where advanced AI is embedded directly into clinical workflows, enabling a meaningful shift in speed and accessibility. In a recent discussion with Rebecca Clyde, Co-founder and CEO of Botco.ai, we discussed how this approach connects patients, physicians, and trial sponsors while red

A Reflection by Désirée Goubert, PhD, & Henning Mann, PhD; HM.BioConsulting Download PDF here: There is something quietly profound about the idea that human tissue models have now travelled beyond low Earth orbit, circled the moon, and returned. As a first, not as a vision or grant proposal, let alone a symbolic gesture, but indeed as working and applied biological systems designed to answer a very practical question: how does the human body respond to extreme environments?

Christian Maass, PhD, Principal Scientist & Lead, MPSlabs, ESQLabs GmbHHenning Mann, PhD, Founder & CEO, HM.BioConsulting, former Sen. Dir Applied Sciences, Nortis, Inc. Download the full article: Overview Over the past decade, Organ-on-Chip (OoC) platforms have matured into powerful microphysiological systems (MPS) capable of recapitulating dynamic human cellular microenvironments. Yet, widespread adoption in pharmaceutical and regulatory workflows has lagged, in many case

Mini StartUp Review & Example for Fractional BD Opportunity By Henning Mann, PhD | HM.BioConsulting 3–5 minute read Download the File “Longevity research is evolving. AI and automation are accelerating drug discovery. In this space Ora Biomedical is one to watch.” Background: Aging as a Modifiable Endpoint Aging is the single greatest risk factor for most chronic diseases, yet for decades, drug discovery pipelines have focused on treating symptoms rather than addressing upstr

Download the article: A conversation between Elizabeth (Lizzy) Crist, Business Development Manager & Technical Lead (USA), AIM Biotech and Henning Mann, PhD, Founder & CEO, HM.BioConsulting, former Sen. Dir. Applied Science, Nortis Inc., Executive Intro With the FDA, NIH, and GAO each advancing the shift toward human-based preclinical models , Organ-on-Chip (OoC) and broader Microphysiological Systems (MPS) technologies have been moved into the spotlight and given unprecede

Review Opinion: Henning Mann, PhD, HM.BioConsulting LLC Download PDF: The more conversations we have with clients and prospects, the more...

Henning Mann, PhD, HM.BioConsulting 🚨 The Policy Shift We've Been Waiting For In 2025, the FDA, in collaboration with the National...

Opinion, Henning Mann, PhD, HM.BioConsulting In today’s tight funding climate and intense competitive pressure, emerging and...